Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$4.14M, compared with $38.01M a year earlier. Trailing-twelve-month net income was -$9.47M.

Context

  • Net income amounted to 27.1% of revenue in FY2025, down 39.2 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$12.99M (-139.7%) for the fiscal year ending Dec 2026, a slowdown from the +138.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.14M+21.7% QoQ
Last fiscal yearDec 2025
$32.69M+138.3% YoY
LTMMar 2026
-$9.47M-39.5% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-110.9%-302.2%-191.3 pp
1 year+138.3%-139.7%-278.0 pp
3-year CAGR—-39.5%—
5-year CAGR+1.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
32.69M USD
Year-over-year change
+138.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -39.5% is the 10th highest of 11, against a peer median of +6.0%.
  • Net income amounts to 40.9% of revenue for ATRA, versus a peer median of 302.7%.
ATRA Competitors
Net Income for ATRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$153.6M USD-37.4%+17.0%154.2%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$110M USD+489.6%——
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
STTKShattuck Labs, Inc.LTM Mar 2026$49.87M USD-29.4%-21.8%4987.4%
IFRXInflaRx N.V.LTM Mar 2026€41.2M EUR-7.9%+14.1%140477.1%
CNTXContext Therapeutics Inc.LTM Mar 2026$40.23M USD+45.6%+34.5%—
CLNNClene Inc.LTM Mar 2026$33.51M USD+15.3%-4.4%25009.7%
OVIDOvid Therapeutics Inc.LTM Mar 2026$24.17M USD-3.2%-31.5%339.3%
COYACoya Therapeutics, Inc.LTM Mar 2026$21.13M USD+23.3%+20.1%266.1%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$9.47M USD-39.5%—40.9%
CSBRChampions Oncology, Inc.LTM Jan 2026$2.34M USD-136.5%+104.7%4.0%
Peer median (excluding ATRA) —+6.0%+14.1%302.7%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.38M
Deferred Income Tax1.79M0000
Stock-Based Compensation53.87M53.84M45.39M27M9.75M
Change in Working Capital52.58M(61.47M)15.34M(30.96M)(104.74M)
Accounts Receivables264K(39.24M)6.11M32.63M229K
Inventory3.34M(1.59M)(8.12M)(4.43M)10.66M
Accounts Payables9.07M(9.21M)(3.13M)687K(4.24M)
Other Working Capital39.91M(11.44M)20.48M(59.84M)(111.38M)
Other Non-Cash Items2.04M(40.15M)17.59M15.59M8.98M
Operating Cash Flow(220.52M)(270.43M)(192.98M)(68.72M)(50.94M)
Capital Expenditures(10.58M)(4.19M)(1.22M)(246K)0
Acquisitions (Net)(32.84M)000948K
Purchases of Investments(301.13M)(180.59M)(83.65M)(19.67M)(7.89M)
Sales of Investments333.97M292.97M208.71M28.54M25.09M
Other Investing Activities32.84M94.77M25K00
Investing Cash Flow22.26M202.96M123.87M8.62M18.15M
Debt Repayment(254K)(518K)(947K)(892K)(250K)
Common Stock Issued98.7M21.89M2.14M59.95M16.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.5M31.71M821K223K(1K)
Financing Cash Flow103.94M53.08M2.01M59.28M16.1M
Effect of Forex Changes00000
Net Change in Cash(94.32M)(14.39M)(67.1M)(811K)(16.69M)
Free Cash Flow(231.1M)(274.62M)(194.2M)(68.96M)(50.94M)

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.